203 related articles for article (PubMed ID: 33891474)
1. Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data.
Turan V; Lambertini M; Lee DY; Wang E; Clatot F; Karlan BY; Demeestere I; Bang H; Oktay K
J Clin Oncol; 2021 Jun; 39(18):2016-2024. PubMed ID: 33891474
[TBL] [Abstract][Full Text] [Related]
2. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
3. Assessment of ovarian reserve and reproductive outcomes in
Ponce J; Fernandez-Gonzalez S; Calvo I; Climent M; Peñafiel J; Feliubadaló L; Teulé A; Lázaro C; Brunet JM; Candás-Estébanez B; Durán Retamal M
Int J Gynecol Cancer; 2020 Jan; 30(1):83-88. PubMed ID: 31780568
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 germline mutations may be associated with reduced ovarian reserve.
Wang ET; Pisarska MD; Bresee C; Chen YD; Lester J; Afshar Y; Alexander C; Karlan BY
Fertil Steril; 2014 Dec; 102(6):1723-8. PubMed ID: 25256924
[TBL] [Abstract][Full Text] [Related]
5. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
Oktay KH; Bedoschi G; Goldfarb SB; Taylan E; Titus S; Palomaki GE; Cigler T; Robson M; Dickler MN
Fertil Steril; 2020 Jun; 113(6):1251-1260.e1. PubMed ID: 32331767
[TBL] [Abstract][Full Text] [Related]
6. Anti-müllerian hormone levels and antral follicle count in women with a BRCA1 or BRCA2 germline pathogenic variant: A retrospective cohort study.
Denis-Laroque L; Drouet Y; Plotton I; Chopin N; Bonadona V; Lornage J; Salle B; Lasset C; Rousset-Jablonski C
Breast; 2021 Oct; 59():239-247. PubMed ID: 34304065
[TBL] [Abstract][Full Text] [Related]
7. Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature.
Hu-Heimgartner K; Lang N; Ayme A; Ming C; Combes JD; Chappuis VN; Vazquez C; Friedlaender A; Vuilleumier A; Bodmer A; Viassolo V; Sandoval JL; Chappuis PO; Labidi-Galy SI
Fam Cancer; 2023 Jul; 22(3):283-289. PubMed ID: 37119509
[TBL] [Abstract][Full Text] [Related]
8. Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk.
Giordano S; Garrett-Mayer E; Mittal N; Smith K; Shulman L; Passaglia C; Gradishar W; Pavone ME
J Adolesc Young Adult Oncol; 2016 Dec; 5(4):337-343. PubMed ID: 27513691
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer.
Park S; Lee E; Park S; Lee S; Nam SJ; Kim SW; Lee JE; Yu JH; Kim JY; Ahn JS; Im YH; Park WY; Park K; Park YH
Mol Cancer Res; 2020 Sep; 18(9):1315-1325. PubMed ID: 32554602
[TBL] [Abstract][Full Text] [Related]
10. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
[TBL] [Abstract][Full Text] [Related]
11. Predominance of
Pujol P; Yauy K; Coffy A; Duforet-Frebourg N; Gabteni S; Daurès JP; Penault Llorca F; Thomas F; Hughes K; Turnbull C; Galibert V; Rideau C; Corsini C; Collet L; You B; Geneviève D; Philippe N
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805038
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.
Koh SJ; Ohsumi S; Takahashi M; Fukuma E; Jung KH; Ishida T; Dai MS; Chang CH; Dalvi T; Walker G; Bennett J; O'Shaughnessy J; Balmaña J
Breast Cancer; 2022 Jan; 29(1):92-102. PubMed ID: 34467476
[TBL] [Abstract][Full Text] [Related]
13. Antimüllerian hormone levels are lower in BRCA2 mutation carriers.
Johnson L; Sammel MD; Domchek S; Schanne A; Prewitt M; Gracia C
Fertil Steril; 2017 May; 107(5):1256-1265.e6. PubMed ID: 28476184
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
[TBL] [Abstract][Full Text] [Related]
15. BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro.
Grynberg M; Dagher Hayeck B; Papanikolaou EG; Sifer C; Sermondade N; Sonigo C
Hum Reprod; 2019 Feb; 34(2):374-379. PubMed ID: 30561604
[TBL] [Abstract][Full Text] [Related]
16. Serum AMH levels in healthy women from BRCA1/2 mutated families: are they reduced?
van Tilborg TC; Derks-Smeets IA; Bos AM; Oosterwijk JC; van Golde RJ; de Die-Smulders CE; van der Kolk LE; van Zelst-Stams WA; Velthuizen ME; Hoek A; Eijkemans MJ; Laven JS; Ausems MG; Broekmans FJ
Hum Reprod; 2016 Nov; 31(11):2651-2659. PubMed ID: 27907901
[TBL] [Abstract][Full Text] [Related]
17. The first Japanese nationwide multicenter study of
Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
[TBL] [Abstract][Full Text] [Related]
18. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation.
Gunnala V; Fields J; Irani M; D'Angelo D; Xu K; Schattman G; Rosenwaks Z
Fertil Steril; 2019 Feb; 111(2):363-371. PubMed ID: 30527950
[TBL] [Abstract][Full Text] [Related]
19. Navigating the body of literature assessing BRCA1/2 mutations and markers of ovarian function: a systematic review and meta-analysis.
Cordeiro Mitchell CN; McGuinness B; Fine E; Kearns WG; Christianson MS; Segars J; Pastore LM
J Assist Reprod Genet; 2020 May; 37(5):1037-1055. PubMed ID: 32212026
[TBL] [Abstract][Full Text] [Related]
20. Do BRCA1 and BRCA2 gene mutation carriers have a reduced ovarian reserve? Protocol for a prospective observational study.
Winship AL; Willson C; Hansen KR; Hutt KJ; Hickey M
BMJ Open; 2019 Nov; 9(11):e033810. PubMed ID: 31772111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
